Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future
| Autor: | Aravinda Thiagalingam, Jim Pouliopoulos, John Swinnen, Sara I. Al Raisi, Pramesh Kovoor |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Resistant hypertension Blood Pressure 030204 cardiovascular system & hematology 03 medical and health sciences Renal Artery 0302 clinical medicine Internal medicine medicine.artery medicine Humans 030212 general & internal medicine Sympathectomy Renal artery Randomized Controlled Trials as Topic Denervation Hypertension treatment business.industry Significant difference Sham control Blood pressure Hypertension Cardiology Cardiology and Cardiovascular Medicine business |
| Zdroj: | Heart, Lung and Circulation. 29:94-101 |
| ISSN: | 1443-9506 |
| DOI: | 10.1016/j.hlc.2019.06.723 |
| Popis: | Early studies of renal artery denervation (RAD) demonstrated efficacy in treating resistant hypertension patients with significant reduction in office blood pressure (BP). This resulted in a growing enthusiasm in the field and a rapid evolution of technology with expanding procedural indications. However, the first randomised sham-controlled trial, Symplicity HTN-3, failed to demonstrate a significant difference in BP reduction between the RAD and the sham control arm, which subsequently led to a major reduction in the clinical application of this procedure. Additionally, the results generated further interest into understanding the mechanism and factors affecting procedural success and identifying the limitations within the field. Many lessons were learned from Symplicity HTN-3 trial, and with recent evidence emerging for RAD in hypertension treatment, the field continues to be refined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect